NEW YORK – Bayer and NeoGenomics on Tuesday launched Test4TRK, a program offering no-cost NTRK gene fusion testing to patients with RAI-refractory differentiated thyroid cancer and metastatic colorectal cancer with high microsatellite instability.
NTRK fusions are known to drive cancers, and since they tend to occur in RAI-refractory differentiated thyroid cancer and metastatic colorectal cancer with MSI-high status, testing patients for this biomarker may aid in their disease management.